Thymoglobulin Versus Alemtuzumab Versus Daclizumab in Living Donor Renal Transplantation

NCT01046955 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

38

Enrollment

OTHER

Sponsor class

Conditions

End-Stage Renal Disease
Living Donors

Interventions

DRUG: Anti-Thymocyte Globulin vs Campath-1H vs Daclizumab

Sponsor

University of Miami

Collaborators

[object Object]